Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.2.781

CYP1A1, GSTM1, GSTT1 and TP53 Polymorphisms and Risk of Gallbladder Cancer in Bolivians  

Sakai, Kazuaki (Division of Preventive Medicine, Niigata University Graduate School of Medical and Dental Sciences)
Loza, Ernesto (Instituto de Gastroenterologia Boliviano-Japones)
Roig, Guido Villa-Gomez (Instituto de Gastroenterologia Boliviano-Japones)
Nozaki, Ryoko (Niigata University of Health and Welfare)
Asai, Takao (Niigata University of Health and Welfare)
Ikoma, Toshikazu (Hokuriku University)
Tsuchiya, Yasuo (Division of Preventive Medicine, Niigata University Graduate School of Medical and Dental Sciences)
Kiyohara, Chikako (Department of Preventive Medicine, Graduate School of Medical Sciences, Kyushu University)
Yamamoto, Masaharu (Niigata University of Health and Welfare)
Nakamura, Kazutoshi (Division of Preventive Medicine, Niigata University Graduate School of Medical and Dental Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.2, 2016 , pp. 781-784 More about this Journal
Abstract
The Plurinational State of Bolivia (Bolivia) has a high incidence rate of gallbladder cancer (GBC). However, the genetic and environmental risk factors for GBC development are not well understood. We aimed to assess whether or not cytochrome P450 (CYP1A1), glutathione S-transferase mu 1 (GSTM1), theta 1 (GSTT1) and tumor suppressor protein p53 (TP53) genetic polymorphisms modulate GBC susceptibility in Bolivians. This case-control study covered 32 patients with GBC and 86 healthy subjects. GBC was diagnosed on the basis of histological analysis of tissues at the Instituto de Gastroenterologia Boliviano-Japones (IGBJ); the healthy subjects were members of the staff at the IGBJ. Distributions of the CYP1A1 rs1048943 and TP53 rs1042522 polymorphisms were assayed using PCR-restriction fragment length polymorphism assay. GSTM1 and GSTT1 deletion polymorphisms were detected by a multiplex PCR assay. The frequency of the GSTM1 null genotype was significantly higher in GBC patients than in the healthy subjects (odds ratio [OR], 2.35; 95% confidence interval [CI], 1.03-5.37; age-adjusted OR, 3.53; 95% CI, 1.29-9.66; age- and sex-adjusted OR, 3.40; 95% CI, 1.24-9.34). No significant differences were observed in the frequencies of CYP1A1, GSTT1, or TP53 polymorphisms between the two groups. The GSTM1 null genotype was associated with increased GBC risk in Bolivians. Additional studies with larger control and case populations are warranted to confirm the association between the GSTM1 deletion polymorphism and GBC risk suggested in the present study.
Keywords
Gallbladder cancer; genetic susceptibility; CYP1A1; GSTM1; GSTT1; TP53;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Lazcano-Ponce EC, Miquel JF, Munoz N, et al (2001). Epidemiology and Molecular Pathology of Gallbladder Cancer. CA Cancer J Clin, 51, 349-64.   DOI
2 Lee MS, Su L, Christiani DC (2010). Synergistic effects of NAT2 slow andGSTM1 null genotypes on carcinogen DNA damage in the Lung. Cancer Epidemiol Biomarkers Prev, 19, 1492-7.   DOI
3 Lemos MC, Coutinho E, Gomes L, et al (2008). Combined GSTM1 and GSTT1 null genotypes are associated with a lower risk of papillary thyroid cancer. J Endocrinol Invest, 31, 542-5.   DOI
4 Mandegary A, Rostami S, Alimoghaddam K, et al (2011). Glutathione-S-transferase T1-null genotype predisposes adults to Acute Promyelocytic Leukemia, a case-control study. Asian Pac J Cancer Prev, 12, 1279-82.
5 Moore LE, Baris DR, Figueroa JD, et al (2011). GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis, 32, 182-9.   DOI
6 Moore SP, Forman D, Pineros M, et al (2014). Cancer in indigenous people in Latin America and the Caribbean: a review. Cancer Med, 3, 70-80.   DOI
7 Orth K, Beger HG (2000). Gallbladder carcinoma and surgical treatment. Langenbecks Arch Surg, 385, 501-8.   DOI
8 Pearson WR, Vorachek WR, Xu SJ, et al (1993). Identification of Class-mu Glutathione Transferase gene GSTM1-GSTM5 on Human Chromosome 1p13. Am J Hum Genet, 53, 220-33.
9 Piao JM, Shin MH, Kim HN, et al (2013). Glutathione-Stransferase (GSTM1, GSTT1) null phenotypes and risk of lung cancer in a Korean population. Asian Pac J Cancer Prev, 14, 7165-9.   DOI
10 Randi G, Franceschi S, La Vecchia C (2006). Gallbladder cancer worldwide. Int J Cancer, 118, 1591-602.   DOI
11 Sobti RC, Kaur P, Kaur S, et al (2008). Combined effect of GSTM1, GSTT1 and GSTP1 polymorphisms on histological subtypes of lung cancer. Biomarkers, 13, 282-95.   DOI
12 Strom BL, Soloway RD, Rios-Dalenz JL, et al (1995). Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer, 76, 1747-6.   DOI
13 Songserm N, Promthet S, Pientong C, et al (2014). Geneenvironment interaction involved in cholangiocarcinoma in the Thai population: polymorphisms of DNA repair genes, smoking and use of alcohol. BMJ Open, 4, 5447.
14 Srivastava K, Srivastava A, Kumar A, et al (2011). Gallbladder cancer predisposition: a multigenic approach to DNA-repair, apoptotic and inflammatory pathway genes. PLoS One, 6, 16449.   DOI
15 Tsuchiya Y, Kiyohara C, Sato T, et al (2007). Polymorphism of cytochrome P450 1A1, glutathione S-transferase class mu, and tumor protein p53 genes and the risk of developing gallbladder cancer in Japanese. Clin Biochem, 40, 881-6.   DOI
16 Tsuchiya Y, Baez S, Calvo A, et al (2010). Evidence that genetic variants of metabolic detoxication and cell cycle control are not related to gallbladder cancer risk in Chilean women. Int J Biol Markers, 25, 75-8.   DOI
17 Voho A, Impivaara O, Jarvisalo J, et al (2006). Distribution of glutathione S-transferase M1, P1 and T1 genotypes in different age-groups of Finns without diagnosed cancer. Cancer Detect Prev, 30, 144-51.   DOI
18 Wistuba II, Gazdar AF (2004). Gallbladder cancer: Lessons from a rare tumor. Nat Rev Cancer, 4, 695-706.   DOI
19 Booth FW, Roberts CK, Laye MJ (2012). Lack of exercise is a major cause of chronic diseases. Compr Physiol, 2, 1143-211.
20 Asai T, Loza E, Roig GV, et al (2014). High Frequency of TP53 but not K-ras gene mutation in Bolivian patients with gallbladder cancer. Asian Pac J Cancer Prev, 15, 5449-54.   DOI
21 Eroglu P, Erkol Inal E, Sag SO, et al (2015). Association analysis of GSTM1, T1 and P1 IIe105Val polymorphism with carpal tunnel syndrome. Clin Rheumatol, 9, 1-7.
22 Gaspar PA, Kvitko K, Papadópolis LG, et al (2002). High frequency of CYP1A1*2C allele in Brazilian population. Hum Biol, 74, 235-42.   DOI
23 Geisler SA, Olshan AF (2001). GSTM1, GSTT1, and the risk of squamous cell carcinoma of the Head and Neck: A mini-HuGE review. Am J Epidemiol, 154, 95-105.   DOI
24 Gu J, Zou H, Zheng L, et al (2014). GSTM1 null genotype is associated with increased risk of gastric cancer in both eversmokers and non-smokers: a meta-analysis of case-control studies. Tumor Biol, 35, 3439-45.   DOI
25 Hayes JD, Pulford DJ (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol, 30, 445-600.   DOI
26 Hundal R, Shaffer EA (2014). Gallbladder cancer: Epidemiology and outcome. Clin Epidemiol, 6, 99-109.
27 Kimura A, Tsuchiya Y, Lang I et al (2008). Effect of genetic predisposition on the risk of gallbladder cancer in Hungary. Asian Pac J Cancer Prev, 9, 391-6.
28 Yuan JM, Chan KK, Coetzee GA, et al (2008). Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis, 29 1386-93.   DOI
29 Wang B, Huang G, Wang D, et al (2010). Null genotype of GSTM1 and GSTT1contribute to hepatocellular carcinoma risk: Evidence from an update meta-analysis. J Hepatol, 53, 508-18.   DOI
30 Wang J, Jiang J, Zhao Y, et al (2011). Genetic polymorphisms of glutathione S-transferase genes and susceptibility to colorectal cancer: A case-control study in an Indian population. Cancer Epidemiol, 35, 66-72.   DOI
31 Zajac A, Smolarz B, Stachowiak G, et al (2014). TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women. Med Oncol, 31, 286.   DOI